JP4950053B2 - ハプトグロビンの単離方法 - Google Patents

ハプトグロビンの単離方法 Download PDF

Info

Publication number
JP4950053B2
JP4950053B2 JP2007537377A JP2007537377A JP4950053B2 JP 4950053 B2 JP4950053 B2 JP 4950053B2 JP 2007537377 A JP2007537377 A JP 2007537377A JP 2007537377 A JP2007537377 A JP 2007537377A JP 4950053 B2 JP4950053 B2 JP 4950053B2
Authority
JP
Japan
Prior art keywords
human
buffer
anion exchange
substrate
elution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007537377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008517046A (ja
JP2008517046A5 (enExample
Inventor
ジョーン ダルトン
エイドリアン ポドモア
ペーター カンパリューム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NHS Blood and Transplant
Original Assignee
NHS Blood and Transplant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NHS Blood and Transplant filed Critical NHS Blood and Transplant
Publication of JP2008517046A publication Critical patent/JP2008517046A/ja
Publication of JP2008517046A5 publication Critical patent/JP2008517046A5/ja
Application granted granted Critical
Publication of JP4950053B2 publication Critical patent/JP4950053B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Semiconductor Lasers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2007537377A 2004-10-19 2005-10-19 ハプトグロビンの単離方法 Expired - Lifetime JP4950053B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0423196.5A GB0423196D0 (en) 2004-10-19 2004-10-19 Method
GB0423196.5 2004-10-19
PCT/GB2005/004037 WO2006043062A1 (en) 2004-10-19 2005-10-19 Method for the isolation of haptoglobin

Publications (3)

Publication Number Publication Date
JP2008517046A JP2008517046A (ja) 2008-05-22
JP2008517046A5 JP2008517046A5 (enExample) 2008-11-27
JP4950053B2 true JP4950053B2 (ja) 2012-06-13

Family

ID=33484812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007537377A Expired - Lifetime JP4950053B2 (ja) 2004-10-19 2005-10-19 ハプトグロビンの単離方法

Country Status (13)

Country Link
US (1) US9145448B2 (enExample)
EP (1) EP1802654B1 (enExample)
JP (1) JP4950053B2 (enExample)
AT (1) ATE539085T1 (enExample)
AU (1) AU2005297061B2 (enExample)
BR (1) BRPI0516933B8 (enExample)
CA (1) CA2584407C (enExample)
ES (1) ES2379157T3 (enExample)
GB (1) GB0423196D0 (enExample)
IL (1) IL182340A (enExample)
MX (1) MX2007004244A (enExample)
PL (1) PL1802654T3 (enExample)
WO (1) WO2006043062A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0423196D0 (en) 2004-10-19 2004-11-24 Nat Blood Authority Method
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins
HK1212995A1 (zh) * 2012-10-03 2016-06-24 Csl Behring Ag 一种纯化蛋白质的方法
EP3917943A4 (en) * 2019-02-01 2022-12-07 Ohio State Innovation Foundation PROTEINS PURIFICATION PROCEDURES
US20220218834A1 (en) * 2019-05-20 2022-07-14 Ohio State Innovation Foundation Apohemoglobin-haptoglobin complexes and methods of using thereof
US20240034749A1 (en) * 2021-02-04 2024-02-01 Green Cross Corporation Method for purification of hemopexin and haptoglobin
CN115531921B (zh) * 2022-08-26 2024-07-16 大连依利特分析仪器有限公司 一种制备型液相色谱馏分收集装置及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061735A (en) * 1973-11-15 1977-12-06 The Green Cross Corporation Haptoglobin in aqueous solution and process for preparing the same
GB1426039A (en) 1973-11-15 1976-02-25 Green Cross Corp Haptoglobin in aqueous solution and process for tits preparation
US4137307A (en) * 1973-11-15 1979-01-30 The Green Cross Corporation Process for preparing haptoglobin aqueous solution using strong anion exchanger
JPS5337406B2 (enExample) * 1973-11-15 1978-10-09
JPS52128205A (en) * 1976-04-16 1977-10-27 Green Cross Corp:The Prophylactic and therapeutic drugs for cerebro-vascular contraction
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5094960A (en) * 1988-10-07 1992-03-10 New York Blood Center, Inc. Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
JP3554796B2 (ja) * 1988-10-31 2004-08-18 三菱ウェルファーマ株式会社 アルブミン製剤及びその製造方法
JP3825061B2 (ja) * 1994-09-28 2006-09-20 三菱ウェルファーマ株式会社 ハプトグロビンの製造方法
DE19960500A1 (de) * 1999-12-15 2001-07-12 Giesing Michael Antikörper und Verfahren zu ihrer Herstellung, deren Verwendung sowie Immunisierungscocktails, Immunoassay-Sets und Peptide
PT1328297E (pt) * 2000-10-16 2010-01-04 Cytoguide Aps Função de um receptor de haptoglobina-hemoglobina e suas utilizações
US20030113830A1 (en) 2001-07-11 2003-06-19 Rappaport Family Institute For Research In The Medical Sciences Novel antioxidant, nucleic acid constructs encoding same, pharmaceutical compositions containing same and use of same for reducing oxidative-stress
JP2004244348A (ja) * 2003-02-13 2004-09-02 Nihon Pharmaceutical Co Ltd パプトグロビンの精製法
GB0423196D0 (en) 2004-10-19 2004-11-24 Nat Blood Authority Method
WO2006107708A1 (en) 2005-04-04 2006-10-12 Alexion Pharmaceuticals, Inc. Treatment of disease caused by excess free hemoglobin

Also Published As

Publication number Publication date
BRPI0516933B8 (pt) 2021-05-25
BRPI0516933A (pt) 2008-09-23
ES2379157T3 (es) 2012-04-23
IL182340A0 (en) 2007-07-24
EP1802654B1 (en) 2011-12-28
AU2005297061A1 (en) 2006-04-27
EP1802654A1 (en) 2007-07-04
MX2007004244A (es) 2007-09-07
JP2008517046A (ja) 2008-05-22
CA2584407C (en) 2015-02-03
AU2005297061B2 (en) 2011-09-01
US20090281282A1 (en) 2009-11-12
IL182340A (en) 2012-06-28
BRPI0516933B1 (pt) 2021-02-09
CA2584407A1 (en) 2006-04-27
GB0423196D0 (en) 2004-11-24
WO2006043062A1 (en) 2006-04-27
ATE539085T1 (de) 2012-01-15
US9145448B2 (en) 2015-09-29
PL1802654T3 (pl) 2012-05-31

Similar Documents

Publication Publication Date Title
JP4445202B2 (ja) 治療的使用のためのヒト免疫グロブリン濃縮物の調製方法
CA2694854C (en) Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
JP2002517516A (ja) 静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法
AU2009270723A1 (en) Method of preparing alpha-1 proteinase inhibitor
CN104968676A (zh) 一种纯化蛋白质的方法
JPH0580455B2 (enExample)
JP4950053B2 (ja) ハプトグロビンの単離方法
FR2676231A1 (fr) Concentre de facteur xi de la coagulation sanguine a haute activite specifique, approprie a usage therapeutique et son procede de preparation.
PL165402B1 (pl) Sposób wydzielania oczyszczonego roztworu albuminy PL
ES2543829T5 (es) Procedimiento para la preparación del inhibidor de proteinasa alfa 1
AU2011331208A1 (en) A process for reduction and/or removal of FXI and FXIa from solutions containing said coagulation factors
TWI593702B (zh) 純化由細胞培養而來的ａｌｐｈａ蛋白酶抑制劑
US8580931B2 (en) Method for the purification of alpha-1-antitrypsin
JPH08225599A (ja) Ｃ１−エステラーゼ阻害剤濃厚物（ｃ１−ｉｎｈ）の調製法、および治療的使用のための得られた濃厚物
CN120943939A (zh) 一种全层析法从血浆中提取人α1-抗胰蛋白酶的方法
Bagheri et al. Quality Evaluation and Comparison of Immunoglobulin Prepared by Two Various Methods of Human Plasma Fractionation: Quality Comparison of Two Fractionation Methods for Human Plasma-Derived IgG
CN120435490A (zh) 用混合模式色谱法纯化血红素结合蛋白的方法
WO2000034453A1 (en) PURIFICATION OF α1-PROTEINASE INHIBITOR
HU200345B (en) Process for producing immunoglobin and albumin by combination of 2-ethoxy-6,9-diaminoacridine and chromatography

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120207

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120308

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150316

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4950053

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250